In the EXIST-1 trial , initiated on Aug 10 , 2009 , more than 35 % of patients with subependymal giant cell astrocytoma ( SEGA ) associated with tuberous sclerosis complex had at least 50 % reduction in SEGA volume after 96 months of treatment with everolimus .